Skip to main content
. 2017 Aug 8;67(8):1484–1492. doi: 10.1136/gutjnl-2017-314178

Figure 5.

Figure 5

Outcome according to ctDNA drop after 2 months of treatment in the PROPSECT-R trial. Kaplan-Meier curves for progression-free survival (A) and overall survival (B) in patients with or without ctDNA drop, (C) spider plot demonstrating depth and duration of response to regorafenib (evaluated by RECIST V.1.1. criteria) according to KEF and ctDNA drop. ctDNA, circulating tumour DNA; KEF, Ktrans× enhancing fraction.